Teva Pharmaceuticals

Teva Pharmaceuticals, headquartered in IL and operating within the Pharmaceutical Preparation Manufacturing industry, has reported its carbon emissions for several years.

For the most recent reporting year, 2025, Teva Pharmaceuticals' total carbon emissions were approximately 1,232,288,000 kg CO2e. This total comprises approximately 229,331,000 kg CO2e from Scope 1 emissions, and approximately 161,989,000 kg CO2e from Scope 2 emissions (market-based). Scope 3 emissions for 2025 accounted for the largest portion, totalling approximately 840,968,000 kg CO2e across various categories, with purchased goods and services being a significant contributor at approximately 2,172,650,000 kg CO2e.

In 2024, total emissions were approximately 1,223,297,000 kg CO2e, with Scope 1 at approximately 241,128,000 kg CO2e and Scope 2 (market-based) at approximately 207,915,000 kg CO2e. Scope 3 emissions in 2024 amounted to approximately 774,254,000 kg CO2e, with purchased goods and services being the largest category at approximately 2,464,952,000 kg CO2e.

Teva Pharmaceuticals has established climate commitments, including a target to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 25% by 2025 and by 46% by 2030, both compared to a 2019 baseline. Furthermore, the company has stated its intention to achieve net-zero emissions across its operations and value chain by 2045. Their Science Based Targets initiative (SBTi) commitments align with these goals, targeting a 46.2% reduction in absolute Scope 1 and 2 GHG emissions by 2030 (from a 2019 base year) and a 25% reduction in absolute Scope 3 GHG emissions by 2030 (from a 2020 base year).